Web of Science: 44 cites, Scopus: 46 cites, Google Scholar: cites,
Design of a surface plasmon resonance immunoassay for therapeutic drug monitoring of amikacin
Losoya Leal, Adrián (Tecnológico de Monterrey)
Estévez, M. Carmen (Institut Català de Nanociència i Nanotecnologia)
Martínez Chapa, Sergio O. (Tecnológico de Monterrey)
Lechuga, Laura M (Institut Català de Nanociència i Nanotecnologia)

Títol variant: Therapeutic Drug Monitoring of Amikacin Using a Surface Plasmon Resonance Biosensor
Data: 2015
Resum: The therapeutic drug monitoring (TDM) of pharmaceutical drugs with narrow therapeutic ranges is of great importance in the clinical setting. It provides useful information towards the enhancement of drug therapies, aiding in dosage control and toxicity risk management. Amikacin is an aminoglycoside antibiotic commonly used in neonatal therapies that is indicated for TDM due to the toxicity risks inherent in its use. Current techniques for TDM such as high performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS) are costly, time consuming, and cannot be performed at the site of action. Over the last decades, surface plasmon resonance (SPR) biosensors have become increasingly popular in clinical diagnostics due to their ability to detect biomolecular interactions in real-time. We present an SPR-based competitive immunoassay for the detection of the antibiotic amikacin, suitable for TDM in both adults and neonates. We have obtained high specificity and sensitivity levels with an IC value of 1. 4 ng/mL and a limit of detection of 0. 13 ng/mL, which comfortably comply with the drug's therapeutic range. Simple dilution of serum can therefore be sufficient to analyze low-volume real samples from neonates, increasing the potential of the methodology for TDM. Compared to current TDM conventional methods, this SPR-based immunoassay can provide advantages such as simplicity, potential portability, and label-free measurements with the possibility of high throughput. This work is the foundation towards the development of an integrated, simple use, highly sensitive, fast, and point-of-care sensing platform for the opportune TDM of antibiotics and other drugs in a clinical setting.
Ajuts: Ministerio de Economía y Competitividad SEV-2013-0295
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió acceptada per publicar
Matèria: Therapeutic drug monitoring ; Surface plasmon resonance ; Amikacin ; Immunoassay
Publicat a: Talanta, Vol. 141 (August 2015) , p. 253-258, ISSN 1873-3573

DOI: 10.1016/j.talanta.2015.04.009


Postprint
17 p, 188.9 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2019-06-12, darrera modificació el 2023-10-01



   Favorit i Compartir